Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ryan Rivers
09.21.23 -- Japan's Global Lessons In Outsourcing
Commercial Readiness With Orca Bio's Dan Kirby Orca Bio's Dan Kirby knows what makes or breaks post-approval commercial efforts, having played virtually every role in drug sales and marketing. Today, Orca is ushering its first cell therapy into Phase 3 trials, with strategically dispersed follow-up candidates spanning all phases back to R&D.
09.21.22 -- Planning For Manufacturing Capacity With Kite Pharma's Will Junker
By Andrew Walsh, Thomas Altmann, Ralph Basile, Joel Bercu, Ph.D., Alfredo Canhoto, Ph.D., Andreas Flueckiger, M.D., Igor Gorsky, Jessica Graham, Ph.D., Ester Lovsin Barle, Ph.D., Ovais Mohammad, Mariann Neverovitch, Siegfried Schmitt, Ph.D., and Osamu Shirokizawa Two of the most common terms used in pharmaceutical cleaning validation are the maximum allowable carryover (MAC or MACO) and the maximum safe carryover (MSC).
09.21.22 -- Should You Hire Talent Away From Your CDMOs?
By Andrew Walsh, Thomas Altmann, Ralph Basile, Joel Bercu, Ph.D., Alfredo Canhoto, Ph.D., Andreas Flueckiger, M.D., Igor Gorsky, Jessica Graham, Ph.D., Ester Lovsin Barle, Ph.D., Ovais Mohammad, Mariann Neverovitch, Siegfried Schmitt, Ph.D., and Osamu Shirokizawa Two of the most common terms used in pharmaceutical cleaning validation are the maximum allowable carryover (MAC or MACO) and the maximum safe carryover (MSC).
05.18.22 -- Overcome Potency Assay Development Challenges In Gene Therapies
By BioPhorum In gene therapy development and manufacturing, developing and validating appropriate potency assays that reflect the mechanism of action acceptable to regulators is a process fraught with challenges. The FDA advocates the use of a matrix approach, and this article shares best practices of this approach.
Benefits Of RABS And Isolator Technology In A Changing Regulatory Landscape
By Ryan Rivers, Shane Mohr, and Lisa DeOerio, Emergent BioSolutions Mitigating risk is a key consideration for pharmaceutical companies when planning their clinical trial material and/or drug product manufacturing processes. One of the most prevalent sources is material handling: every step in the drug substance or drug product manufacturing process can introduce risk.
Benefits Of RABS And Isolator Technology In A Changing Regulatory Landscape
By Ryan Rivers, Shane Mohr, and Lisa DeOerio, Emergent BioSolutions Mitigating risk is a key consideration for pharmaceutical companies when planning their clinical trial material and/or drug product manufacturing processes. One of the most prevalent sources is material handling: every step in the drug substance or drug product manufacturing process can introduce risk.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ryan
Contact Ryan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack